Syngene International Limited has informed the Exchange about Investor Presentation
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syngene International filed its Q1 FY26 investor presentation with the exchanges. Revenue from operations rose 11% year-on-year to Rs 875 Cr (about USD 102 Mn), though it declined 14% sequentially from the previous quarter. Operating EBITDA margin expanded to 23.6% from 21.5% in Q1 FY25, and reported PAT before exceptional items jumped 59% YoY to Rs 87 Cr (PAT margin 10% vs 7%). Key highlights include a clean USFDA inspection of its Human Pharmacology Unit, a favorable VAI outcome for its Biologics facility, inauguration of a new peptide laboratory, and recognition by TIME/Statista as one of the World's Most Sustainable Companies 2025, ranking #1 in India among pharma/biotech firms. The company remains net cash positive at Rs 1,053 Cr, with Biocon Group holding 53% and a free float of 47%.
The YoY margin expansion and PAT growth signal improving operational efficiency, though the QoQ dip reflects typical Q1 seasonality in the CRDMO business rather than weakness. For shareholders, the strong regulatory track record and capacity expansion in biologics and peptides support the long-term growth thesis, but no fresh forward-looking guidance on margins, acquisitions, or order pipeline was disclosed in this routine quarterly filing.